IMPEDIMED LIMITED — Capital/Financing Update 2017

Oct 22, 2017

==> picture [225 x 42] intentionally omitted <==

23 October 2017

ASX ANNOUNCEMENT

Shipments of SOZO[TM] with L-Dex[® ] Commence in the U.S.

Brisbane, Australia and Carlsbad, Calif. - ImpediMed Limited (ASX: IPD) a global provider of medical technology to non-invasively measure, monitor and manage tissue composition and fluid status, is pleased to announce the initial shipments of SOZO[TM] systems with L-Dex[® ] technology to customers in the U.S.

This new platform allows for more effective and efficient patient care. Being a connected device allows large institutions the option of placing devices in multiple locations and integrating the data into a single patient record. The system is being sold to hospitals and clinicians with an annual licensing contract for the ongoing usage of SOZO. Existing customers will be the initial target for the first phase of the commercial launch in the U.S.

“The initial feedback on SOZO from clinicians have been very positive. In addition to these early shipments, we have received feedback from many existing customers that are looking to add more SOZO units than U400s, and they have started including SOZO purchases in their current budgets,” commented Richard Carreon, Managing Director and CEO of ImpediMed. “A number of our largest customers will be expanding their programs from testing only high-risk breast cancers patients to all cancer survivors who are at risk of developing unilateral lymphedema in their upper or lower extremities.”

Richard Carreon Managing Director & CEO

For further information, contact:

Richard Carreon, ImpediMed Managing Director & CEO Morten Vigeland, ImpediMed CFO T: +1 (760) 585-2100

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@we-buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with U.S. offices in Carlsbad, Calif. and Bloomington, Minn., and a European office in Thessaloniki, Greece, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed was the first company to receive FDA clearance in the U.S. to aid healthcare professionals to clinically assess unilateral lymphoedema of the arm and leg in women and the leg in men, for its L-Dex[®] device. In addition, ImpediMed produces a family of

FDA cleared and CE Marked medical devices, including SOZO[TM] , sold in select markets globally.

For more information, visit www.impedimed.com.